This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Free CME: e-Report

Evidence-Based Treatment and Monitoring Strategies for Dementia-Related Psychosis

Clive Ballard, MBChB, MMedSci, MRCPsych, MDa

Published: April 27, 2021

Atypical antipsychotics play a limited role in the management of dementia-related psychosis (DRP). Major adverse outcomes are associated with most antipsychotics in patients with dementia, and guidelines recommend that these drugs not be prescribed for long durations. When treating symptoms of DRP, clinicians should follow guidelines such as using medication only if the patient or others are in distress or danger and starting with low doses. Novel antipsychotics or alternative agents may offer superior efficacy and safety.


See the entire activity

To cite: Ballard C. Evidence-based treatment and monitoring strategies for dementia-related psychosis. J Clin Psychiatry. 2021;82(3):AD19038BR4C.
To share: https://doi.org/10.4088/JCP.AD19038BR4C

© Copyright 2021 Physicians Postgraduate Press, Inc.

aUniversity of Exeter College of Medicine and Health, UK

 

Volume: 82

Quick Links: Dementia , Geriatric , Neurologic and Neurocognitive , Psychotic Disorders

References

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Sublingual Dexmedetomidine for the Treatment of Acute Agitation in Adults With Schizophrenia or Schizoaffective Disorder: A Randomized Placebo-Controlled Trial

This RCT determined whether a single dose of sublingual dexmedetomidine reduced acute agitation associated with schizophrenia or...

Read More...